BC
WVE icon

Bridgefront Capital’s Wave Life Sciences WVE Stock Holding History

Bridgefront Capital’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$589K Buy
101,454
+89,308
+735% +$592K 0.16% 222
2026
Q1 		$88.1K Buy
+12,146
New +$158K 0.02% 502

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

Bridgefront Capital's WVE Position: Q2 2026 in Review

Bridgefront Capital increased its Wave Life Sciences (WVE) stake by 735% in Q2 2026, buying an estimated $592K and bringing the position to 101,454 shares worth $589K. The position accounts for 0.16% of the portfolio, ranked #222.

Bridgefront Capital first reported a position in WVE in Q1 2026 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • Bridgefront Capital held 101,454 shares of Wave Life Sciences worth $589K as of Q2 2026.
  • Bridgefront Capital bought 89,308 Wave Life Sciences shares in Q2 2026, an estimated $592K.
  • Wave Life Sciences made up 0.16% of Bridgefront Capital's portfolio in Q2 2026, its #222 holding.
  • Bridgefront Capital first reported a position in Wave Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.